Key result
Metformin treatment in patients with advanced HFrEF and type 2 diabetes was associated with significantly better event-free survival compared to other glucose-lowering agents in a propensity score-matched analysis.
Why the study?
The role of metformin in the treatment of patients with advanced HFrEF and type 2 diabetes mellitus is not firmly established.
Does metformin improve survival and quality of life in patients with advanced HFrEF and type 2 diabetes mellitus?
Population
847 stable patients with advanced HFrEF, including 380 with DM
Comparison
Metformin vs other glucose-lowering agents
Design
Prospective cohort study with propensity score-matched analysis
Follow-up
Median of 1126 days
Authors
Loading...
Should not yet change practice in advanced HFrEF with T2DM; hypothesis-generating and requires randomized confirmation.
Observational (n=847)
No
Does metformin improve survival and quality of life in patients with advanced HFrEF and type 2 diabetes mellitus?
p-value: p=0.01
Metformin treatment in patients with advanced HFrEF and type 2 diabetes is associated with better quality of life and improved survival, independent of glycemic control.
Beneš et al. (2022) conducted an observational in Advanced heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (n=847). Metformin vs. Other glucose-lowering agents (metformin-free) was evaluated on Combined endpoint of death, urgent heart transplantation (HTx) or mechanical circulatory support (MCS) implantation (p=0.01). Metformin treatment in patients with advanced HFrEF and type 2 diabetes was associated with significantly better event-free survival compared to other glucose-lowering agents in a propensity score-matched analysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: